Wim Mol is a life sciences executive with 30 years of experience in the biopharmaceutical industry. He joined Immunovo as CEO in 2017. Prior to that he served 7 years as the CEO of Pepscan Holding NV. During his tenure at Pepscan he transformed the company from a hybrid research and services organisation into a focussed and profit generating peptide services company. He successfully spun off Immunovo from Pepscan, as well as Catapult Therapeutics BV, a single asset company developing a first in class antibody for hematological cancers.
Before joining Pepscan he was VP at Schering-Plough, responsible for the late stage development and market introduction planning of a novel oral contraceptive. Prior to that he worked with Organon Pharmaceuticals in various international management positions, leading companies in the USA, Chile, The Netherlands and the Middle East. Wim Mol holds a Msc in Pharmacy and a PhD in Pharmacology, both from the University of Groningen.